Low-intensity treatment of hematological disorders
US12370207B2 · kind B2 · utility
0Cited by
10References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 3, 2021 |
| Grant date | Jul 29, 2025 |
| Priority date | — |
| Expiry date | Mar 3, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K39/3955
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.